

This author's PDF version corresponds to the article as it appeared upon acceptance. Fully formatted PDF versions will be made available soon.

Skeletal muscle mass indexes and nonalcoholic fatty liver disease in Chinese elders

doi: 10.6133/apjcn.202107/PP.0001

Published online: July 2021

Running title: Muscle mass and nonalcoholic fatty liver disease

Chong Wang MD^{1,2}, Xiao-fei Guo PhD^{1,2}, Ting Yang MD^{1,2}, Wen-jun Ma MD^{1,2}, Ting Zhao MD³, Duo Li PhD^{1,2,4}

¹Institute of Nutrition & Health, Qingdao University, Qingdao, China

²School of Public Health, Qingdao University, Qingdao, China

³Affiliated Hospital of Qingdao University, Qingdao, China

⁴Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China

Authors' email addresses and contributions:

Chong Wang: 2018020872@qdu.edu.cn

Contribution: contributed to data collection, data analysis and writing manuscript.

Xiao-fei Guo: guoxf@qdu.edu.cn

Contribution: conceived and designed the research, and contributed to reviewing or revising the paper.

Ting Yang: 2018020867@qdu.edu.cn

Contribution: participated in the collection of anthropometric parameters and body composition data.

Wen-jun Ma: m17865201076@163.com

Contribution: participated in the collection of anthropometric parameters and body composition data.

Ting Zhao: zhaoting@qduhospital.cn

Contribution: participated in the collection of anthropometric parameters and body composition data.

Duo Li: duoli@qdu.edu.cn

Contribution: conceived and designed the research, and contributed to reviewing or revising the paper.

Corresponding Author: Prof. Duo Li, Institute of Nutrition & Health, Qingdao University, 308 Ningxia Road, Qingdao, China. Tel: 86-532-82991018. Email: duoli@qdu.edu.cn

ABSTRACT

Background and Objectives: As an endocrine organ, the mass of skeletal muscle is closely related to human health. The present study aimed to investigate the relationship between regional skeletal muscle and nonalcoholic fatty liver disease (NAFLD) in Chinese elders. **Methods and Study Design:** A total of 1,328 participants (579 males and 749 females), aged 65 to 96 years were recruited between March to November 2020 in Qingdao, China. Of these, 400 cases and 400 healthy controls, matched by gender and age (± 3 years), were included in the study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and body weight was adopted to standardize skeletal muscle mass to obtain skeletal muscle mass indexes. **Results:** Inverse associations were observed for trunk muscle mass index (TMI) (OR=0.42; 95% CI: 0.19, 0.93; p for trend=0.083) and leg skeletal muscle mass index (LMI) (OR=0.41; 95% CI: 0.18, 0.97; p for trend=0.012) with NAFLD risk after adjustment for age, body mass index, glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, dietary intakes of energy, carbohydrate, protein and fat, smoking, alcohol drinking, education and physical activity. Dose-response analysis indicated that per standard deviation increment of LMI was associated with 23% (95%CI: 0.63, 0.95) reduction of NAFLD risk. **Conclusions:** The present study demonstrates that higher TMI and LMI are associated with a lower NAFLD risk.

Key Words: nonalcoholic fatty liver disease, skeletal muscle mass indexes, elders, case-control study, epidemiology

INTRODUCTION

Nonalcoholic fatty liver diseases (NAFLD) are the most prevalent chronic liver disease, affecting about one quarter of the world's population.¹ It has been estimated that the prevalence of NAFLD was approximately 20.1-29.2% in Chinese adults.^{2,3} Changes of lifestyle as well as environment exert significant effects responsible for the initiation and progress of NAFLD. As a progressive disease, NAFLD would potentially progress from simple steatosis into nonalcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma and death.⁴ Although NAFLD patients are asymptomatic in the initial stage, substantial evidence has demonstrated that NAFLD is associated with obesity, diabetes and other metabolic diseases, posing a major threat to public health.⁵⁻⁷

Skeletal muscle is an important endocrine organ for insulin-mediated glucose uptake and utilization, and plays an important role in glucose homeostasis and insulin resistance (IR).

Besides, it participates in the processes of autocrine, paracrine, endocrine and inflammation.⁸⁻
¹⁰ Although a growing body of studies have shown inverse associations of total skeletal muscle mass and appendicular skeletal muscle mass (ASM) with NAFLD risk,¹¹⁻¹³ no study has focused on the relationship between regional skeletal muscle mass and NAFLD risk. Interestingly, one study demonstrated that the biological function of adipose tissue was location-related, and the distribution of adipose tissue in the upper and lower body showed an opposite biological function.¹⁴ This study gives us a hint and raises a question: does the distribution of skeletal muscle show a similar pattern to adipose tissue? In addition, aging is significantly correlated with muscle mass loss and NAFLD incidence, respectively.^{15,16} Therefore, the aim of the present study is to investigate the association between regional skeletal muscle and NAFLD risk, achieving this, we have conducted a population-based study to explore the relationship between regional skeletal muscle and NAFLD risk in Chinese elders.

MATERIALS AND METHODS

Study design and participants

China has a sound basic medical insurance system, which sets up electronic health records for people over 65 years and provides free annual healthy check-up. Of these, 1,328 participants (579 males and 749 females) aged 65 to 96 years free-living in 2 neighborhoods (Fushan and Ningxia Community, Qingdao) completed the healthy examination at the local community service center between March to November 2020. Participants with lack of skeletal muscle mass data (n=190), or/and 3-day 24-hour dietary food records (n=17) were excluded in the study. Finally, 1,121 participants (493 males and 628 females) completed questionnaire and body composition analysis.

NAFLD was defined when participants' abdominal ultrasound diagnosed as fatty liver disease and weekly alcohol consumption ≤ 140 grams for males and ≤ 70 grams for females, excluding viral or autoimmune liver disease. The ultrasonic diagnostic criteria of fatty liver was based on the standard of the Chinese Liver Diseases Association.¹⁷ To identify eligible NAFLD cases, the exclusion criteria were included: (1) malignancy or a history of malignancy, dementia, organ failure and so on; (2) specific diseases that could lead to steatosis, such as viral hepatitis, drug induced liver disease, total parenteral nutrition, Wilson's disease and autoimmune liver disease; (3) missing data on abdominal ultrasonography; (4) weekly alcohol consumption ≥ 140 grams for males and ≥ 70 grams for females, or excessive alcohol consumption in the past 12 months.¹⁷ Ultimately, 471 participants were diagnosed as

NAFLD, including 148 males and 323 females; the prevalence rate was 42%. Of these, 400 NAFLD patients were randomly selected as the cases. The controls were a random sample of those two neighborhoods that participated in physical check-up during the same period. Exclusion criteria were the same as cases, and abdominal ultrasonography confirmed the absence of fatty liver in the control group. Controls were individually matched to cases by age (± 3 y) and gender. This study protocols were approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (Qingdao University, China), and were carried out in accordance with the approved guidelines. Prior to participant this study, all participants provided written informed consent.

Muscle mass assessment and definition of muscle mass index

As a widely applied and effective method for assessing body composition, bioelectrical impedance analysis (BIA, InBodyS10, Biospace) was implemented to measure skeletal muscle mass after an overnight fasting.^{18,19} Participants were instructed to sit quietly for 10 minutes to achieve a normal distribution of body fluids. The measurement process was performed by a professional nutritionist in accordance with the manufacturer's instructions. InBodyS10 used a z-axis for impedance, analyzed intracellular, extracellular fluid values and water content; and an x-axis for reactance, measured body cell mass. The InBodyS10 measured impedance of 5 regions of the body (trunk, right and left arms, and right and left legs).²⁰

After obtaining each regional muscle mass using BIA, the skeletal muscle mass of each region was standardized by body weight to obtain the skeletal muscle mass index (SMI). For example, the appendicular skeletal muscle mass index (ASMI) was calculated by dividing the sum of the ASM in the bilateral upper and lower four limbs (kg) by body weight (kg) and expressed as a percentage = $(ASM/body\ weight) \times 100\%$.^{19,21} Except for ASMI, total skeletal muscle mass index (TSMI), trunk muscle mass index (TMI), arm skeletal muscle mass index (AMI) and leg skeletal muscle mass index (LMI) were also calculated, respectively.

Questionnaire

Face-to-face interviews were performed to collect information demographic parameters, anthropometric parameters, lifestyles, chronic disease history, medication history, family genetic history and physical activity. In addition, 3-day 24-hour dietary records (2 working days and 1 weekend) were used to evaluate the energy and nutrients intake of the participants.

Energy and nutrients were calculated by using the dietary software Nutrition system of Traditional Chinese Medicine Combining with Western Medicine (NCCWMX2/NCCW12.0). Dietary diversity score (DDS) was calculated by 3-day 24-hour dietary records.²² A minor modulation was performed to assess food groups, namely dairy; eggs, fish, shrimp, and meat; rice and grains; fruits; vegetables; beans; fat and oil, as previous reported.²² The trial scored one point for each food groups, and the DDS score ≤ 5 and > 5 were regarded as low- and high- dietary diversity, respectively.²³

The physical activity of the participants was assessed with the physical activity scale for the elderly (PASE).²⁴ The physical activity index (PAI) was divided into low (≤ 123.6), medium (123.6-158.9) and high (> 158.9), respectively.

Anthropometrical Measurements

Anthropometric measurements were implemented by trained investigators using standard methods, including height (m), weight (kg), waist circumference (WC) (cm), hip circumference (HC) (cm) and blood pressure (mmHg). Body mass index (BMI, kg/m^2) was calculated by dividing weight in kilograms by height in square meters.

Biochemical measurement

Fasting venous blood sample was obtained in into vacuum tubes, and the serum was collected for centrifugation at 3000 rpm for 15 minutes at 4°C. Biochemical indicators, in terms of hepatic functions and cardio-metabolic risk factors, were determined by automatic biochemical analyzer (Accute TBA-40FR autoanalyser, Toshiba, Japan) at the Affiliated Hospital of Qingdao University.

Statistical analysis

Shapiro-Wilk test was used to check the normal distribution of continuity variables. Data with normal distribution was represented by mean \pm standard deviation (SD), while skewed variables were represented by median (interquartile rage). Normal distribution variables were compared by t-test, skewed variables were compared by rank sum test, and categorical variables were analyzed by chi-square test (χ^2).

The associations between NAFLD and regional SMIs were analyzed by fitting conditional logistic regression model. SMIs were divided into quartiles according to its distribution. Crude and multivariable-adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were

calculated for NAFLD risk across quartiles of SMIs, with the lowest quartile as the reference. Multivariable-adjusted model was estimated by adjusting for the age, BMI, glucose (GLU), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), energy, protein, fat, carbohydrate, smoking status (yes/no), alcohol drinking status (yes/no), education level (primary/secondary/high) and physical activity. Trend test was performed by assigning a median value to each category and modeling the variables as continuous variables.²⁵

A restricted cubic model with four nodes located in the 5th, 35th, 65th, and 95th percentiles of the exposure distribution in the adjusted model. Dose-response relationships between SMIs and NAFLD risk were evaluated by binary logistic regression models. The non-linear p value was calculated by testing the null hypothesis that the coefficient of the second spline was equal to zero. In addition, spearman correlation analysis was used to analyze the correlations between SMIs and anthropometric and biochemical parameters. Statistical analyses were performed by Stata 15.0 (Stata CORP, College Station, TX, USA), and two-tailed $p < 0.05$ was considered as statistically significant.

RESULTS

Characteristics and dietary intake

Compared with the controls, the NAFLD cases tended to have significantly higher body weight, BMI, alanine transaminase (ALT), GLU, TG, higher systolic blood pressure (SBP) and diastolic blood pressure (DBP). No significant difference was found with respect to age, height, aspartate aminotransferase (AST), TC, LDL-C, HDL-C, and education levels between two groups. There were also significant differences among smoking and drinking status (Table 1). The dietary energy and various nutrients have no significant difference between the case and control groups (Table 2).

Muscle mass indexes and NAFLD risk

Participants in the highest quartiles of TSMI (OR=0.48; 95% CI: 0.30, 0.76; p for trend=0.006), ASMI (OR=0.36; 95% CI: 0.22, 0.59; p for trend=0.001), TMI (OR=0.33; 95% CI: 0.21, 0.53; p for trend <0.001) and LMI (OR=0.28; 95% CI: 0.17, 0.46; p for trend <0.001) showed a significantly negative association with NAFLD risk compared with the references in crude logistic regression model, respectively (Table 3 and Figure 1 a and b). After adjusting for age, BMI, GLU, TC, TG, LDL-C, HDL-C, energy, protein, fat, carbohydrate, smoking status, alcohol drinking status, education level and physical activity, the association remained

significantly regarding TMI (OR=0.42; 95% CI: 0.19, 0.93; p for trend=0.083) and LMI (OR=0.41; 95% CI: 0.18, 0.97; p for trend=0.012) (Figure 1 a and b). No significant correlations were found between AMI and NAFLD risk in crude (OR=1.03; 95% CI: 0.65, 1.64; p for trend=0.661) and multivariable-adjusted models (OR=0.77; 95% CI: 0.36, 1.65; p for trend=0.685) (Table 3).

The associations between NAFLD and muscle mass indexes in stratified by DDS are shown in Table 4. For participants' DDS ≤ 5 , the highest quartile of LMI (OR=0.43; 95% CI: 0.23, 0.81; p for trend=0.024), was negatively associated with NAFLD risk compared with the lowest quartile in crude model. For participants' DDS > 5 , the highest quartile of ASMI (OR=0.56; 95% CI: 0.34, 0.93; p for trend=0.011), TMI (OR=0.42; 95% CI: 0.25, 0.71; p for trend=0.001) and LMI (OR=0.42; 95% CI: 0.25, 0.71; p for trend=0.001), were negatively associated with NAFLD risk compared with the lowest quartile in crude model. However, no significant associations were found between NAFLD risk and muscle mass indexes in the multivariable-adjusted model.

The associations between NAFLD and muscle mass indexes in stratified by PAI are shown in Table 5. For participants' PAI ≤ 123.6 , the highest quartile of TMI (OR=0.43; 95% CI: 0.20, 0.92; p for trend=0.027) was negatively association with NAFLD risk compared with the lowest quartile in crude model. For participants' $123.6 < \text{PAI} \leq 158.9$, the highest quartile of TSMI (OR=0.36; 95% CI: 0.18, 0.72; p for trend=0.005), ASMI (OR=0.43; 95% CI: 0.22, 0.86; p for trend=0.011), TMI (OR=0.24; 95% CI: 0.12, 0.47; p for trend ≤ 0.001) and LMI (OR=0.33; 95% CI: 0.17, 0.66; p for trend=0.001) were negatively association with NAFLD risk in crude model. The significant correlations between muscle mass indexes and NAFLD risk were disappeared after adjustment for potential confounding factors.

By using restricted cubic model, a significant linear relationship was observed between LMI (p for non-linearity=0.217, p for linearity=0.005) and NAFLD risk, but not for TMI (p for non-linearity=0.331, p for linearity=0.099) (Figure 1 c and d). Dose-response analysis indicated that per SD increment of LMI was associated with 23% (95%CI: 0.63, 0.95; p for trend=0.014) reduction of NAFLD risk.

Correlation between muscle mass indexes and cardio-metabolic parameters

Spearman correlation analysis showed that TSMI was negatively associated with BMI ($r=-0.403$, $p < 0.001$), SBP ($r=-0.111$, $p=0.002$), WC ($r=-0.231$, $p < 0.001$), HC ($r=-0.218$, $p < 0.001$) and GLU ($r=-0.079$, $p=0.026$), respectively. ASMI was negatively associated with BMI ($r=-$

0.364, $p < 0.001$), SBP ($r = -0.127$, $p < 0.001$), WC ($r = -0.181$, $p < 0.001$), HC ($r = -0.155$, $p < 0.001$) and GLU ($r = -0.085$, $p = 0.016$), respectively. TMI was negatively associated with BMI ($r = -0.459$, $p < 0.001$), SBP ($r = -0.092$, $p = 0.010$), WC ($r = -0.292$, $p < 0.001$), HC ($r = -0.275$, $p < 0.001$) and GLU ($r = -0.097$, $p = 0.006$), respectively. LMI was negatively associated with BMI ($r = -0.429$, $p < 0.001$), SBP ($r = -0.152$, $p < 0.001$), DBP ($r = -0.075$, $p = 0.035$), WC ($r = -0.235$, $p < 0.001$), HC ($r = -0.208$, $p < 0.001$), GLU ($r = -0.107$, $p < 0.002$) and TG ($r = -0.086$, $p = 0.015$), respectively. AMI was negatively associated with BMI ($r = -0.103$, $p = 0.004$), HDL-C ($r = -0.091$, $p = 0.011$) and TC ($r = -0.094$, $p = 0.008$), respectively, and positively associated with ALT ($r = 0.084$, $p = 0.018$) (Figure 2).

DISCUSSION

In the present study, higher TMI and LMI were associated with a lower risk of NAFLD after adjustment for potential confounding factors. No significant associations were found between TSMI, ASMI, AMI and NAFLD risk. The findings of this study supported the hypothesis that lower muscle mass was positively associated with NAFLD risk, and different region muscle masses might perform different physiological functions.

Skeletal muscle mass, as an independent factor, is associated with NAFLD risk.²⁶⁻²⁸ Cross-sectional studies have reported that higher ASMI and TSMI are inversely associated with NAFLD risk in different age groups.^{11,13,28} Longitudinal study also demonstrated that increment in ASMI over time had favorable effects in prevention and remission of existing NAFLD.²¹ However, it has been unclear whether regional muscle mass indexes are associated with NAFLD risk. In the present study, higher TMI and LMI were associated with reduced NAFLD risk in multivariate-adjusted model, indicating that TMI and LMI were independently associated with NAFLD risk. Previous study showed that higher leg and arm muscle masses to total body weight ratio could actively prevent metabolic syndrome.²⁹ Inconsistent with previous studies, no statistical significance was found with respect to AMI associated with NAFLD risk.

Dietary factors and physical activities play a pivotal role in the initiation and development of NAFLD.^{30,31} Therefore, stratified analysis was performed to investigate whether DDS and PAI exerted the associations between muscle mass and NAFLD risk. Considering small sample-size and individual differences, no significant association was observed between muscle mass and NAFLD risk in stratified analysis after adjustment for confounding factors. We further explored the associations of SMIs with anthropometric and cardio-metabolic parameters. The results indicated that except for AMI, other SMIs, especially LMI, were

negatively correlated with almost all anthropometric parameters, such as BMI, blood pressure, WC and HC. Elevated anthropometric parameters were associated with increasing risk of NAFLD.^{32,33} The negative association between SMIs and NAFLD risk might be mediated by lowering these anthropometric parameters. Except for AMI, other SMIs also negatively correlated with blood glucose. Lower blood glucose can improve IR status and reduce the risk of diabetes in the elderly, thereby protecting against NAFLD.³⁴ In addition, LMI was negatively correlated with TG. Thus, appropriate muscle mass is critical for maintaining healthy anthropometric and biochemical parameters.

The mechanisms to explain why a higher skeletal muscle mass protected against NAFLD was summarized as follows (Figure 3). First, skeletal muscle is a glucose utilizing organ in response to insulin, and low skeletal muscle mass reduces glucose utilization and induces IR.^{35,36} IR and its induced hyperinsulinemia can up-regulate sterol regulatory element binding protein-1c (SREBP-1c) expression and promotes the synthesis of excess TG in the liver.³⁷ SREBP-1c mainly expresses in liver, muscle and adipose tissue.³⁸ AMP-activated protein kinase (AMPK) activation via muscle exercise,³⁹ and high skeletal muscle mass might down-regulate SREBP-1c expression. Second, skeletal muscle, as an endocrine organ, triggers and releases myokines.⁴⁰ Irisin, an exercise-inducible myokine, can increase β -oxidation in the liver.⁴¹ It has been shown that irisin concentration is inversely associated with intrahepatic TG in obesity.⁴² Consequently, low muscle mass might contribute to fatty liver disease by decreasing secretion of beneficial myokines. Third, age-related sarcopenia generally accompanies inflammatory disorders, forms chronic low-grade inflammatory status, increases concentration of pro-inflammatory cytokine such as tumor necrosis factor- α (TNF- α) and C-reactive protein (CRP).^{36,43} TNF- α in the liver promotes fat accumulation and accelerates the formation of NAFLD by activating de novo fat synthesis.⁴⁴ The increase of CRP correlates with hepatic steatosis.⁴⁵ Fourth, sarcopenia patients tend to have high adipose mass.⁴⁶ Increased adipose tissue in the body results in decreased adiponectin secretion.⁴⁷ While studies have found that adiponectin can improve lipid oxidation, reduce insulin resistance, and improve the inflammatory state of body.^{48,49} Exercise plays a beneficial role in inhibiting the pathogenesis of NAFLD,⁵⁰ simple exercise interventions (not changing diet) have shown to dramatically lower intrahepatic fat.⁵¹ In the present study, there was a significant negative correlation between LMI and NAFLD risk, but not in AMI, we hypothesized that the leg muscles might play a crucial role in physical activities than arms.

The advantages of the present study deserve to be mentioned. First, this is the first study to investigate the association between regional skeletal muscle and NAFLD in China, indicating

that the distribution of skeletal muscle might exert differential physiological functions. Second, using face-to-face interviews, the basic information is comprehensively collected regarding diet, lifestyle, and anthropometric parameters. Again, the community-based case-control design is more representative than hospital-based case-control studies. Nonetheless, several shortcomings in the study should be noted. First, this study is an observational study, the causal relationship between skeletal muscle and NAFLD cannot determine. Randomized controlled trials should be conducted to illuminate causal correlation between skeletal muscle mass and NAFLD. Second, the correlation between NAFLD severity and skeletal muscle mass may be different, and the severity of NAFLD is not classified in the present study. In addition, the correlation between skeletal muscle function (grip strength, gait speed, etc.) and NAFLD is not explored. Hence, skeletal muscle mass and function were combined to explore their correlation with NAFLD is a tendency in the further study. Third, the present study was conducted in elderly aged over 65 years, so the current results could not be generalized to the entire Chinese population.

The present study provides substantial evidence that the higher trunk muscle and leg skeletal muscle are associated with a lower risk of NAFLD. Appropriate exercise and dietary intake to maintain skeletal muscle mass of the trunk and legs are of great significance to the prevention of NAFLD in the elderly.

ACKNOWLEDGEMENTS

We appreciate faculty and staff at Fushan and Ningxia Community Hospital for their supports on the study.

CONFLICT OF INTEREST AND FUNDING DISCLOSURE

The authors declare no conflict of interest. This work was supported by the National Natural Science Foundation of China (NSFC: 81773433 and 82073538) and by the 2018 Chinese Nutrition Society (CNS) Nutrition Research Foundation-DSM Research Fund (CNS-DSM2018A30). The funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73-84. doi: 10.1002/hep.28431.

2. Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. *Hepatology*. 2019;70:1119-33. doi: 10.1002/hep.30702.
3. Ma Q, Yang F, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. *Hepatol Int*. 2021;15:127-36. doi: 10.1007/s12072-020-10132-z.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology*. 2005;129:113-21. doi: 10.1053/j.gastro.2005.04.014.
5. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. *PLoS Med*. 2020;17:e1003100. doi: 10.1371/journal.pmed.1003100.
6. Kim D, Adejumo AC, Yoo ER, Iqbal U, Li AA, Pham EA, Cholankeril G, Glenn JS, Ahmed A. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. *Gastroenterology*. 2019;157:1055-66.e11. doi: 10.1053/j.gastro.2019.06.026.
7. Gao X, Tian Y, Randell E, Zhou H, Sun G. Unfavorable associations between serum trimethylamine N-oxide and L-carnitine levels with components of metabolic syndrome in the Newfoundland population. *Front Endocrinol (Lausanne)*. 2019;10:168. doi: 10.3389/fendo.2019.00168.
8. Pratesi A, Tarantini F, Di Bari M. Skeletal muscle: an endocrine organ. *Clin Cases Miner Bone Metab*. 2013;10:11-4. doi: 10.11138/ccmbm/2013.10.1.011.
9. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. *Diabetologia*. 2005;48:634-42. doi: 10.1007/s00125-005-1682-x.
10. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. *J Pharmacol Sci*. 2014;125:125-31. doi: 10.1254/jphs.14r02cp.
11. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. *Hepatology*. 2014;59:1772-8. doi: 10.1002/hep.26716.
12. Kwon Y, Jeong SJ. Relative skeletal muscle mass is an important factor in non-alcoholic fatty liver disease in non-obese children and adolescents. *J Clin Med*. 2020;9. doi: 10.3390/jcm9103355.
13. Pacifico L, Perla FM, Andreoli G, Grieco R, Pierimarchi P, Chiesa C. Nonalcoholic Fatty liver disease is associated with low skeletal muscle mass in overweight/obese youths. *Front Pediatr*. 2020;8:158. doi: 10.3389/fped.2020.00158.
14. Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes. *Nat Rev Endocrinol*. 2015;11:90-100. doi: 10.1038/nrendo.2014.185.

15. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. *Eur J Clin Nutr.* 2001;55:663-72. doi: 10.1038/sj.ejcn.1601198.
16. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. *World J Gastroenterol.* 2012;18:237-43. doi: 10.3748/wjg.v18.i3.237.
17. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). *J Dig Dis.* 2011;12:38-44. doi: 10.1111/j.1751-2980.2010.00476.x.
18. Kim M, Shinkai S, Murayama H, Mori S. Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population. *Geriatr Gerontol Int.* 2015;15:1013-22. doi: 10.1111/ggi.12384.
19. Petta S, Ciminnisi S, Di Marco V, Cabibi D, Cammà C, Licata A, Marchesini G, Craxì A. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2017;45:510-8. doi: 10.1111/apt.13889.
20. Sillanpää E, Cheng S, Häkkinen K, Finni T, Walker S, Pesola A et al. Body composition in 18- to 88-year-old adults--comparison of multifrequency bioimpedance and dual-energy X-ray absorptiometry. *Obesity (Silver Spring).* 2014;22:101-9. doi: 10.1002/oby.20583.
21. Kim G, Lee SE, Lee YB, Jun JE, Ahn J, Bae JC et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. *Hepatology.* 2018;68:1755-68. doi: 10.1002/hep.30049.
22. Lo YC, Wahlqvist ML, Huang YC, Chuang SY, Wang CF, Lee MS. Medical costs of a low skeletal muscle mass are modulated by dietary diversity and physical activity in community-dwelling older Taiwanese: a longitudinal study. *Int J Behav Nutr Phys Act.* 2017;14:31. doi: 10.1186/s12966-017-0487-x.
23. Lee MS, Huang YC, Su HH, Lee MZ, Wahlqvist ML. A simple food quality index predicts mortality in elderly Taiwanese. *J Nutr Health Aging.* 2011;15:815-21. doi: 10.1007/s12603-011-0081-x.
24. Sattler MC, Jaunig J, Tösch C, Watson ED, Mokkink LB, Dietz P, van Poppel MNM. Current Evidence of Measurement Properties of Physical Activity Questionnaires for Older Adults: An Updated Systematic Review. *Sports Med.* 2020;50:1271-315. doi: 10.1007/s40279-020-01268-x.
25. Larsson SC, Virtamo J, Wolk A. Total and specific fruit and vegetable consumption and risk of stroke: a prospective study. *Atherosclerosis.* 2013;227:147-52. doi: 10.1016/j.atherosclerosis.2012.12.022.
26. Kim HY, Kim CW, Park CH, Choi JY, Han K, Merchant AT, Park YM. Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. *Hepatobiliary Pancreat Dis Int.* 2016;15:39-47. doi: 10.1016/s1499-3872(15)60030-3.

27. Wang YM, Zhu KF, Zhou WJ, Zhang Q, Deng DF, Yang YC, Lu WW, Xu J, Yang YM. Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in Zhejiang Province, China: a cross-sectional observational study. *BMC Geriatr.* 2021;21:55. doi: 10.1186/s12877-020-01910-3.
28. Gan D, Wang L, Jia M, Ru Y, Ma Y, Zheng W et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. *Clin Nutr.* 2020;39:1124-30. doi: 10.1016/j.clnu.2019.04.023.
29. Kim YH, So WY. A low arm and leg muscle mass to total body weight ratio is associated with an increased prevalence of metabolic syndrome: The Korea National Health and Nutrition Examination Survey 2010-2011. *Technol Health Care.* 2016;24:655-63. doi: 10.3233/thc-161162.
30. Gonzalez A, Valero-Breton M, Huerta-Salgado C, Achiardi O, Simon F, Cabello-Verrugio C. Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Transl Myol.* 2021;31. doi: 10.4081/ejtm.2021.9630.
31. Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G. Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals. *Int J Prev Med.* 2016;7:98. doi: 10.4103/2008-7802.188083.
32. Tanaka S, Fujishiro M, Watanabe K, Imatake K, Suzuki Y, Abe M, Ishihara H, Tani S. Effect of adult weight gain on non-alcoholic fatty liver disease and its association with anthropometric parameters in the lean Japanese population. *Diagnostics (Basel).* 2020;10. doi: 10.3390/diagnostics10110863.
33. Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, Koutli E, Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? *Eur J Gastroenterol Hepatol.* 2018;30:979-85. doi: 10.1097/meg.0000000000001191.
34. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol.* 2019;71:793-801. doi: 10.1016/j.jhep.2019.06.021.
35. Jorgensen RA. Nonalcoholic Fatty liver disease. *Gastroenterol Nurs.* 2003;26:150-4; quiz 4-5. doi: 10.1097/00001610-200307000-00003.
36. Zhai Y, Xiao Q. The common mechanisms of sarcopenia and NAFLD. *Biomed Res Int.* 2017;2017:6297651. doi: 10.1155/2017/6297651.
37. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J Clin Invest.* 2008;118:829-38. doi: 10.1172/jci34275.
38. Guo XF, Yang B, Tang J, Li D. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. *Clin Nutr.* 2018;37:113-22. doi: 10.1016/j.clnu.2017.01.003.
39. O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jørgensen SB, Schertzer JD et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. *Proc Natl Acad Sci U S A.* 2011;108:16092-7. doi: 10.1073/pnas.1105062108.

40. Pedersen BK. The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk. *J Physiol.* 2009;587:5559-68. doi: 10.1113/jphysiol.2009.179515.
41. Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. *Nat Rev Endocrinol.* 2017;13:324-37. doi: 10.1038/nrendo.2016.221.
42. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. *J Hepatol.* 2013;59:557-62. doi: 10.1016/j.jhep.2013.04.030.
43. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. *Curr Opin Clin Nutr Metab Care.* 2012;15:12-22. doi: 10.1097/MCO.0b013e32834dd297.
44. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. *Digestion.* 2011;83:124-33. doi: 10.1159/000318741.
45. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). *J Hepatol.* 2015;63:486-93. doi: 10.1016/j.jhep.2015.02.051.
46. Kim TN, Yang SJ, Yoo HJ, Lim KI, Kang HJ, Song W et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. *Int J Obes (Lond).* 2009;33:885-92. doi: 10.1038/ijo.2009.130.
47. Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. *Hepatology.* 2017;66:2055-65. doi: 10.1002/hep.29420.
48. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism.* 2016;65:1038-48. doi: 10.1016/j.metabol.2015.12.012.
49. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. *Diabetes.* 2006;55:924-8. doi: 10.2337/diabetes.55.04.06.db05-0985.
50. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. *Hepatology.* 2010;52:370-81. doi: 10.1002/hep.23711.
51. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol.* 2012;57:157-66. doi: 10.1016/j.jhep.2012.02.023.

Table 1. General characteristic of study participants by NAFLD[†]

Characteristics	Case (n=400)	Control (n=400)	<i>p</i> [‡]
Age (year)	72 (68, 77)	71 (68, 75)	0.160
Sex (%)			1.000
Male	100 (25)	100 (25)	
Female	300 (75)	300 (75)	
Height (cm)	160 (155.5, 165.5)	160 (156, 165.5)	0.907
Weight (kg)	69.2 (63.3, 77.0)	62.5 (55.1, 69.8)	<0.001
BMI (kg/m ²)	26.9 (25.3, 28.9)	24.0 (22.2, 26.2)	<0.001
ALT (U/L)	25.0 (19.0, 35.0)	19.5 (15.0, 26.0)	<0.001
AST (U/L)	24.0 (20.0, 29.0)	23.0 (20.0, 27.0)	0.063
GLU (mmol/L)	6.1 (5.5, 7.3)	5.5 (5.1, 6.4)	<0.001
TG (mmol/L)	1.7 (1.2, 2.5)	1.2 (0.9, 1.8)	<0.001
TC (mmol/L)	6.1 (5.0, 7.0)	6.2 (5.2, 7.1)	0.220
LDL-C (mmol/L)	2.9 (2.3, 3.4)	3.0 (2.4, 3.5)	0.457
HDL-C (mmol/L)	2.0 (1.6, 2.3)	2.0 (1.7, 2.3)	0.217
SBP (mmHg)	137.0 (130.0, 152.0)	135.0 (126.0, 145.5)	0.001
DBP (mmHg)	79.0 (72.0, 85.0)	76.0 (69.0, 83.0)	0.001
Lifestyle factors, n (%)			
Physical activity index			0.745
Low (\leq 123.6)	153 (38.3)	144 (38.8)	
Medium (123.6-158.9)	131 (32.8)	113 (30.5)	
High (>158.9)	115 (28.8)	114 (30.7)	
Smoking status			0.034
Yes	21 (5.3)	33 (9.2)	
No	379 (94.7)	325 (90.8)	
Alcohol drinking status			<0.001
Yes	28 (7.0)	66 (18.4)	
No	372 (93.0)	293 (81.6)	
Educational level			0.387
Primary (\leq 6 y)	89 (22.3)	73 (20.2)	
Secondary (6-12 y)	269 (67.2)	239 (20.2)	
High (>12 y)	42 (10.5)	49 (13.6)	

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; DBP: diastolic blood pressure; GLU: glucose; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; SBP: systolic blood pressure; TG: triglyceride; TC: total cholesterol.

[†]Data are presented as median (interquartile range) for continuous variables with non-normal distributions or participants (percentage %) for categorical variables.

[‡]*p* for difference between groups was tested by chi-square and Wilcoxon rank sum test, respectively.

Table 2. Average daily intake of major nutrients of the subjects[†]

Dietary nutrients	Case (n=400)	Control (n=400)	<i>p</i> [‡]
Energy (kcal)	1723.3 (1510.5, 2025.3)	1740.1 (1453.9, 2033.4)	0.536
Protein (g)	57.9 (45.3, 70.9)	59.5 (46.3, 70.3)	0.599
Carbohydrate (g)	209.7 (170.6, 255.1)	205.1 (163.6, 246.5)	0.077
Fat (g)	73.1 (62.3, 87.2)	73.3 (60.8, 89.4)	0.776
Vitamin A (μgRE)	460.3 (287.0, 684.4)	411.8 (277.7, 653.6)	0.211
Vitamin B ₁ (mg)	0.8 (0.6, 1.0)	0.8 (0.6, 1.0)	0.770
Vitamin B ₂ (mg)	1.1 (0.8, 1.3)	1.1 (0.8, 1.3)	0.971
Vitamin C (mg)	110.6 (74.4, 157.5)	105.5 (70.9, 155.5)	0.748
Vitamin E (mg)	27.9 (23.5, 32.8)	27.2 (22.9, 33.4)	0.340
Vitamin PP (mg)	10.9 (8.3, 14.3)	10.9 (8.2, 14.7)	0.928
Potassium (mg)	1912.3 (1522.6, 2431.3)	1926.4 (1446.3, 2434.7)	0.784
Sodium (mg)	3204.7 (2885.2, 3750.2)	3196.0 (2881.6, 3689.5)	0.601
Calcium (mg)	452.9 (340.0, 612.9)	489.9 (337.5, 687.5)	0.099
Magnesium (mg)	272.5 (226.9, 353.5)	284.2 (217.0, 360.0)	0.685
Iron (mg)	17.4 (13.5, 21.0)	16.7 (13.1, 20.7)	0.496
Manganese (mg)	4.3 (3.3, 5.3)	4.1 (3.2, 5.3)	0.382
Zinc (mg)	7.9 (6.3, 9.7)	7.9 (6.1, 9.6)	0.835
Cuprum (mg)	1.5 (1.1, 2.0)	1.5 (1.1, 2.0)	0.619
Phosphorus (mg)	951.9 (773.9, 1142.5)	979.2 (767.9, 1186.7)	0.424
Selenium (μg)	41.3 (27.4, 60.9)	43.7 (29.2, 61.4)	0.377
Fiber (g)	13.8 (10.5, 18.6)	13.2 (9.9, 18.9)	0.388
SFA (g)	17.4 (14.7, 20.9)	17.3 (14.7, 21.1)	0.831
MUFA (g)	15.4 (13.3, 18.6)	15.3 (13.1, 19.1)	0.935
PUFA (g)	9.9 (7.7, 12.9)	10.2 (7.7, 13.1)	0.468
TFA (g)	43.8 (36.9, 51.9)	41.5 (33.5, 51.8)	0.063

SFA: saturated fatty acid; MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; TFA: total fatty acid.

[†]Data are presented as median (interquartile range).

[‡]*p* for difference between groups was tested by Wilcoxon rank sum test.

Table 3. Associations between muscle mass indexes and NAFLD risk

	Quartile of muscle mass				<i>p</i> for trend
	Q1	Q2	Q3	Q4	
TSMI					
Range (%)	<34.87	34.87-37.76	37.76-41.86	>41.86	
Case/Control (n)	111/90	113/86	91/109	85/115	
Crude OR (95%CI)	1 (Ref.)	1.05 (0.69, 1.59)	0.60 (0.39, 0.91)	0.48 (0.30, 0.76)	0.006
Adjusted OR (95%CI)	1 (Ref.)	1.12 (0.54, 2.32)	0.86 (0.43, 1.70)	0.62 (0.28, 1.38)	0.379
ASMI					
Range (%)	<25.61	25.61-27.99	27.99-31.06	>31.06	
Case/Control (n)	114/87	113/87	90/109	83/117	
Crude OR (95%CI)	1 (Ref.)	0.95 (0.64, 1.42)	0.48 (0.31, 0.75)	0.36 (0.22, 0.59)	0.001
Adjusted OR (95%CI)	1 (Ref.)	1.74 (0.82, 3.69)	0.65 (0.31, 1.36)	0.50 (0.21, 1.17)	0.294
AMI					
Range (%)	<6.53	6.53-7.12	7.12-7.98	>7.98	
Case/Control (n)	96/104	106/92	98/103	100/101	
Crude OR (95%CI)	1 (Ref.)	1.23 (0.84, 1.81)	1.01 (0.67, 1.54)	1.03 (0.65, 1.64)	0.661
Adjusted OR (95%CI)	1 (Ref.)	1.29 (0.66, 2.53)	0.82 (0.40, 1.67)	0.77 (0.36, 1.65)	0.685

Model was adjusted for age, body mass index, glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, dietary intakes of energy, carbohydrate, protein and fat, smoking, alcohol drinking, education and physical activity.

Table 4. Associations between muscle mass indexes and NAFLD risk stratified by DDS

	DDS ≤5					DDS >5				
	Quartile of muscle mass				<i>p</i> for trend	Quartile of muscle mass				<i>p</i> for trend
	Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4	
TSMI										
Range (%)	<34.87	34.87-37.76	37.76-41.86	>41.86		<34.87	34.87-37.76	37.76-41.86	>41.86	
Case/Control (n)	45/35	54/35	39/33	32/43		66/55	59/51	52/76	53/72	
Crude OR (95%CI)	1 (Ref.)	1.20 (0.65, 2.22)	0.82 (0.48, 1.74)	0.58 (0.31, 1.09)	0.213	1 (Ref.)	0.96 (0.57, 1.62)	0.57 (0.34, 0.94)	0.61 (0.37, 1.02)	0.032
Adjusted OR (95%CI)	1 (Ref.)	1.26 (0.59, 2.68)	1.25 (0.56, 2.77)	1.11 (0.45, 2.74)	0.639	1 (Ref.)	1.26 (0.64, 2.47)	1.12 (0.57, 2.19)	0.96 (0.47, 1.97)	0.893
ASMI										
Range (%)	<25.61	25.61-27.99	27.99-31.06	>31.06		<25.61	25.61-27.99	27.99-31.06	>31.06	
Case/Control (n)	47/36	50/26	43/39	30/45		67/51	63/61	47/70	53/72	
Crude OR (95%CI)	1 (Ref.)	1.47 (0.77, 2.80)	0.84 (0.46, 1.56)	0.51 (0.27, 0.96)	0.117	1 (Ref.)	0.79 (0.47, 1.30)	0.51 (0.30, 0.86)	0.56 (0.34, 0.93)	0.011
Adjusted OR (95%CI)	1 (Ref.)	1.43 (0.66, 3.12)	0.95 (0.44, 2.07)	0.94 (0.38, 2.30)	0.945	1 (Ref.)	1.27 (0.66, 2.46)	0.86 (0.43, 1.74)	1.05 (0.51, 2.16)	0.908
TMI										
Range (%)	<29.03	29.03-30.68	30.68-33.15	>33.15		<29.03	29.03-30.68	30.68-33.15	>33.15	
Case/Control (n)	47/34	53/29	42/36	28/47		70/49	58/60	55/67	47/78	
Crude OR (95%CI)	1 (Ref.)	1.32 (0.70, 2.49)	0.84 (0.45, 1.58)	0.43 (0.23, 0.82)	0.068	1 (Ref.)	0.68 (0.40, 1.13)	0.57 (0.34, 0.96)	0.42 (0.25, 0.71)	0.001
Adjusted OR (95%CI)	1 (Ref.)	1.23 (0.58, 2.62)	0.99 (0.44, 2.23)	0.87 (0.36, 2.09)	0.970	1 (Ref.)	0.70 (0.36, 1.36)	1.22 (0.60, 2.47)	0.62 (0.30, 1.28)	0.339
AMI										
Range (%)	<6.53	6.53-7.12	7.12-7.98	>7.98		<6.53	6.53-7.12	7.12-7.98	>7.98	
Case/Control (n)	38/39	46/32	46/36	40/39		58/65	60/60	52/67	60/62	
Crude OR (95%CI)	1 (Ref.)	1.48 (0.78, 2.78)	1.31 (0.70, 2.45)	1.05 (0.56, 1.98)	0.631	1 (Ref.)	1.12 (0.68, 1.85)	0.87 (0.52, 1.44)	1.08 (0.66, 1.79)	0.921
Adjusted OR (95%CI)	1 (Ref.)	0.80 (0.37, 1.71)	1.07 (0.48, 2.39)	1.08 (0.47, 2.51)	0.949	1 (Ref.)	1.41 (0.74, 2.69)	0.95 (0.49, 1.86)	1.25 (0.62, 2.52)	0.572
LMI										
Range (%)	<18.93	18.93-20.82	20.82-23.33	>23.33		<18.93	18.93-20.82	20.82-23.33	>23.33	
Case/Control (n)	49/33	54/30	37/36	30/47		70/48	58/58	55/72	47/76	
Crude OR (95%CI)	1 (Ref.)	1.21 (0.65, 2.27)	0.69 (0.37, 1.31)	0.43 (0.23, 0.81)	0.024	1 (Ref.)	0.69 (0.41, 1.15)	0.52 (0.32, 0.87)	0.42 (0.25, 0.71)	0.001
Adjusted OR (95%CI)	1 (Ref.)	1.51 (0.71, 3.18)	0.88 (0.39, 1.99)	1.04 (0.42, 2.57)	0.824	1 (Ref.)	1.22 (0.62, 2.39)	0.88 (0.44, 1.74)	0.82 (0.39, 1.69)	0.686

DDS: XXXX; TSMI: XXXX; etc

Model was adjusted for age, body mass index, glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, dietary intakes of energy, carbohydrate, protein and fat, smoking, alcohol drinking, education and physical activity.

Table 5. Associations between muscle mass indexes and NAFLD risk stratified by PAI

	PAI ≤ 123.6					123.6 < PAI ≤ 158.9				
	Quartile of muscle mass				<i>p</i> for trend	Quartile of muscle mass				<i>p</i> for trend
	Q1	Q2	Q3	Q4		Q1	Q2	Q3	Q4	
TSMI										
Range (%)	<34.87	34.87-37.76	37.76-41.86	>41.86		<34.87	34.87-37.76	37.76-41.86	>41.86	
Case/Control (n)	48/36	32/28	27/30	15/21		44/25	50/29	40/44	28/44	
Crude OR (95%CI)	1(Ref.)	0.86 (0.44, 1.67)	0.68 (0.34, 1.33)	0.54 (0.24, 1.18)	0.124	1 (Ref.)	0.98 (0.50, 1.92)	0.52 (0.27, 0.99)	0.36 (0.18, 0.72)	0.005
Adjusted OR (95%CI)	1(Ref.)	0.85 (0.36, 1.98)	1.15 (0.46, 2.88)	1.15 (0.38, 3.45)	0.885	1 (Ref.)	1.06 (0.48, 2.36)	0.79 (0.35, 1.78)	0.66 (0.26, 0.71)	0.492
ASMI										
Range (%)	<25.61	25.61-27.99	27.99-31.06	>31.06		<25.61	25.61-27.99	27.99-31.06	>31.06	
Case/Control (n)	50/38	29/24	30/29	13/24		40/24	57/30	34/45	31/43	
Crude OR (95%CI)	1 (Ref.)	0.92 (0.46, 1.82)	0.79 (0.41, 1.52)	0.41 (0.19, 0.91)	0.088	1 (Ref.)	1.14 (0.58, 2.23)	0.45 (0.23, 0.89)	0.43(0.22, 0.86)	0.011
Adjusted OR (95%CI)	1 (Ref.)	1.07 (0.45, 2.60)	0.91 (0.37, 2.22)	0.92 (0.31, 2.78)	0.902	1 (Ref.)	1.46 (0.66, 3.21)	0.68 (0.29, 1.60)	0.93 (0.37, 2.36)	0.904
TMI										
Range (%)	<29.03	29.03-30.68	30.68-33.15	>33.15		<29.03	29.03-30.68	30.68-33.15	>33.15	
Case/Control (n)	46/30	36/30	23/29	17/26		50/26	50/32	37/30	25/54	
Crude OR (95%CI)	1 (Ref.)	0.78 (0.40, 1.53)	0.52 (0.25, 1.06)	0.43 (0.20, 0.92)	0.027	1 (Ref.)	0.81 (0.42, 1.56)	0.64 (0.33, 1.26)	0.24 (0.12, 0.47)	<0.001
Adjusted OR (95%CI)	1 (Ref.)	0.91 (0.39, 2.13)	0.77 (0.30, 1.97)	0.87 (0.30, 2.51)	0.678	1 (Ref.)	0.74 (0.35, 1.61)	0.87 (0.36, 2.08)	0.41 (0.17, 1.03)	0.139
AMI										
Range (%)	<6.53	6.53-7.12	7.12-7.98	>7.98		<6.53	6.53-7.12	7.12-7.98	>7.98	
Case/Control (n)	37/39	34/23	27/35	24/18		40/33	51/41	40/28	31/40	
Crude OR (95%CI)	1(Ref.)	1.56 (0.78, 3.12)	0.81 (0.41, 1.60)	1.41 (0.66, 3.00)	0.597	1 (Ref.)	1.03 (0.55, 1.90)	1.18 (0.60, 2.30)	0.64 (0.33, 1.23)	0.404
Adjusted OR (95%CI)	1(Ref.)	1.57 (0.65, 3.79)	0.45 (0.17, 1.18)	1.36 (0.47, 3.94)	0.983	1 (Ref.)	1.07 (0.51, 2.25)	1.08 (0.46, 2.50)	0.91 (0.38, 2.19)	0.967
LMI										
Range (%)	<18.93	18.93-20.82	20.82-23.33	>23.33		<18.93	18.93-20.82	20.82-23.33	>23.33	
Case/Control (n)	46/35	36/27	26/25	14/28		44/23	54/28	34/44	30/47	
Crude OR (95%CI)	1 (Ref.)	1.01 (0.52,1.97)	0.79 (0.39,1.60)	0.38 (0.17,0.83)	0.066	1 (Ref.)	1.01 (0.51,1.99)	0.40 (0.21,0.79)	0.33 (0.17,0.66)	0.001
Adjusted OR (95%CI)	1 (Ref.)	1.68 (0.72,3.93)	1.10 (0.43,2.79)	1.31 (0.44,3.90)	0.485	1 (Ref.)	1.47 (0.66,3.28)	0.68 (0.28,1.61)	0.79 (0.31,2.01)	0.717

NAFLD:XX; PAI: XXX; TSMI: XXXX

Model was adjusted for age, body mass index, glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, dietary intakes of energy, carbohydrate, protein and fat, smoking, alcohol drinking and education.

Table 5. Associations between muscle mass indexes and NAFLD risk stratified by PAI (cont.)

	PAI > 158.9				<i>p</i> for trend
	Quartile of muscle mass				
	Q1	Q2	Q3	Q4	
TSMI					
Range (%)	<34.87	34.87-37.76	37.76-41.86	>41.86	
Case/Control (n)	19/29	31/29	24/35	42/50	
Crude OR (95%CI)	1 (Ref.)	1.63 (0.76, 3.52)	1.05 (0.48, 2.28)	1.28 (0.63, 2.61)	0.566
Adjusted OR (95%CI)	1 (Ref.)	2.39 (0.80, 7.11)	1.56 (0.54, 4.47)	1.86 (0.66, 5.26)	0.229
ASMI					
Range (%)	<25.61	25.61-27.99	27.99-31.06	>31.06	
Case/Control (n)	24/25	27/33	26/35	39/50	
Crude OR (95%CI)	1 (Ref.)	0.85 (0.40, 1.82)	0.77 (0.36, 1.65)	0.81 (0.40, 1.64)	0.523
Adjusted OR (95%CI)	1 (Ref.)	1.15 (0.40, 3.27)	0.87 (0.30, 2.50)	1.09 (0.39, 3.04)	0.905
TMI					
Range (%)	<29.03	29.03-30.68	30.68-33.15	>33.15	
Case/Control (n)	21/27	25/27	37/44	33/45	
Crude OR (95%CI)	1 (Ref.)	1.19 (0.54, 2.62)	1.08 (0.53, 2.22)	0.94 (0.46, 1.95)	0.952
Adjusted OR (95%CI)	1 (Ref.)	1.23 (0.40, 3.76)	1.89 (0.66, 5.42)	1.45 (0.47, 4.41)	0.397
AMI					
Range (%)	<6.53	6.53-7.12	7.12-7.98	>7.98	
Case/Control (n)	19/32	21/28	31/40	45/43	
Crude OR (95%CI)	1 (Ref.)	1.26 (0.57, 2.82)	1.31 (0.63, 2.73)	1.76 (0.87, 3.56)	0.131
Adjusted OR (95%CI)	1 (Ref.)	0.77 (0.26, 2.29)	1.41 (0.50, 4.00)	1.69 (0.59, 4.83)	0.352
LMI					
Range (%)	<18.93	18.93-20.82	20.82-23.33	>23.33	
Case/Control (n)	29/23	22/33	32/39	33/48	
Crude OR (95%CI)	1 (Ref.)	0.53 (0.25, 1.14)	0.65 (0.32, 1.34)	0.55 (0.27, 1.10)	0.094
Adjusted OR (95%CI)	1 (Ref.)	0.55 (0.19, 1.66)	0.65 (0.23, 1.84)	0.67 (0.23, 1.93)	0.389

NAFLD:XX; PAI: XXX; TSMI: XXXX

Model was adjusted for age, body mass index, glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, dietary intakes of energy, carbohydrate, protein and fat, smoking, alcohol drinking and education.




Figure 1. a: Association of trunk muscle mass index with NAFLD. Number of participants in each quartile (case/control): Q1, 117/83; Q2, 111/89; Q3, 97/103; Q4, 75/125; b: Q1, 119/81; b: Association of leg skeletal muscle mass index with NAFLD. Number of participants in each quartile (case/control): Q2, 112/88; Q3, 92/108; Q4, 77/123. c: Dose-response relationship between trunk muscle mass index increase and NAFLD risk. d: Dose-response relationship between leg skeletal muscle mass index increase and NAFLD risk. The solid line and dashed line represent the estimated ORs and the corresponding 95% CIs, respectively.




Figure 2. Correlation between muscle mass indexes and anthropometric parameters and biochemical indicator. The intensity of the colours represents the degree of association between muscle mass indexes and anthropometric parameters and biochemical indicator as measured by the Spearman correlations. The significance level was adjusted using the Bonferroni method. * $p < 0.05$, ** $p < 0.01$.




Figure 3. The possible mechanisms between skeletal muscle and NAFLD risk. Abbreviations: IL-1 β , interleukin-1 β ; IL-6, interleukin-1; TNF- α , tumor necrosis factor- α ; CRP, C-reaction protein; FA, fatty acid; TG, triglyceride; FFAs, free fatty acids; AMPK, AMP-activated protein kinase; SREBP-1c, sterol regulatory element binding protein-1c; NAFLD, non-alcoholic fatty liver disease.